Literature DB >> 28994452

Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group.

P C D Bank1, K E Caudle2, J J Swen1, R S Gammal2,3, M Whirl-Carrillo4, T E Klein4, M V Relling2, H-J Guchelaar1.   

Abstract

Both the Clinical Pharmacogenetics Implementation Consortium (CPIC) and Dutch Pharmacogenetics Working Group provide therapeutic recommendations for well-known gene-drug pairs. Published recommendations show a high rate of concordance. However, as a result of different guideline development methods used by these two consortia, differences between the published guidelines exist. The aim of this paper is to compare both initiatives and explore these differences, with the objective to achieve harmonization.
© 2017 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh：

Year:  2017        PMID： 28994452      PMCID： PMC5723247          DOI： 10.1002/cpt.762

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  73 in total

1.  Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients.

Authors:  A de Vos; J van der Weide; H M Loovers
Journal:  Pharmacogenomics J       Date:  2010-06-08       Impact factor: 3.550

2.  CYP2D6*36 gene arrangements within the cyp2d6 locus: association of CYP2D6*36 with poor metabolizer status.

Authors:  Andrea Gaedigk; L Dianne Bradford; Sarah W Alander; J Steven Leeder
Journal:  Drug Metab Dispos       Date:  2006-01-13       Impact factor: 3.922

Review 3.  Pharmacogenomics knowledge for personalized medicine.

Authors:  M Whirl-Carrillo; E M McDonagh; J M Hebert; L Gong; K Sangkuhl; C F Thorn; R B Altman; T E Klein
Journal:  Clin Pharmacol Ther       Date:  2012-10       Impact factor: 6.875

4.  The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting.

Authors:  Ankie M Harmsze; Jochem W van Werkum; Christian M Hackeng; Hendrik J T Ruven; Johannes C Kelder; Heleen J Bouman; Nicoline J Breet; Jurriën M Ten Berg; Olaf H Klungel; Anthonius de Boer; Vera H M Deneer
Journal:  Pharmacogenet Genomics       Date:  2012-03       Impact factor: 2.089

5.  Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing.

Authors:  K E Caudle; A E Rettie; M Whirl-Carrillo; L H Smith; S Mintzer; M T M Lee; T E Klein; J T Callaghan
Journal:  Clin Pharmacol Ther       Date:  2014-08-06       Impact factor: 6.875

6.  Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.

Authors:  M Eichelbaum; N Spannbrucker; B Steincke; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

Review 7.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing.

Authors:  R S Gammal; M H Court; C E Haidar; O F Iwuchukwu; A H Gaur; M Alvarellos; C Guillemette; J L Lennox; M Whirl-Carrillo; S S Brummel; M J Ratain; T E Klein; B R Schackman; K E Caudle; D W Haas
Journal:  Clin Pharmacol Ther       Date:  2015-11-09       Impact factor: 6.875

8.  Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers.

Authors:  Julia Kirchheiner; Ingolf Meineke; Gunnar Müller; Ivar Roots; Jürgen Brockmöller
Journal:  Pharmacogenetics       Date:  2002-10

9.  Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium.

Authors:  C H van der Wouden; A Cambon-Thomsen; E Cecchin; K C Cheung; C L Dávila-Fajardo; V H Deneer; V Dolžan; M Ingelman-Sundberg; S Jönsson; M O Karlsson; M Kriek; C Mitropoulou; G P Patrinos; M Pirmohamed; M Samwald; E Schaeffeler; M Schwab; D Steinberger; J Stingl; G Sunder-Plassmann; G Toffoli; R M Turner; M H van Rhenen; J J Swen; H-J Guchelaar
Journal:  Clin Pharmacol Ther       Date:  2017-03       Impact factor: 6.875

10.  Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process.

Authors:  Kelly E Caudle; Teri E Klein; James M Hoffman; Daniel J Muller; Michelle Whirl-Carrillo; Li Gong; Ellen M McDonagh; Katrin Sangkuhl; Caroline F Thorn; Matthias Schwab; Jose A G Agundez; Robert R Freimuth; Vojtech Huser; Ming Ta Michael Lee; Otito F Iwuchukwu; Kristine R Crews; Stuart A Scott; Mia Wadelius; Jesse J Swen; Rachel F Tyndale; C Michael Stein; Dan Roden; Mary V Relling; Marc S Williams; Samuel G Johnson
Journal:  Curr Drug Metab       Date:  2014-02       Impact factor: 3.731
View more
  62 in total

Review 1.  Essential Characteristics of Pharmacogenomics Study Publications.

Authors:  Caroline F Thorn; Michelle Whirl-Carrillo; Houda Hachad; Julie A Johnson; Ellen M McDonagh; Mark J Ratain; Mary V Relling; Stuart A Scott; Russ B Altman; Teri E Klein
Journal:  Clin Pharmacol Ther       Date:  2019-01       Impact factor: 6.875

2.  Pharmacogenetics: Chasing Perfection.

Authors:  Andrea Gaedigk
Journal:  Clin Pharmacol Ther       Date:  2019-08       Impact factor: 6.875

3.  Implementation and obstacles of pharmacogenetics in clinical practice: An international survey.

Authors:  Elizabeth Abou Diwan; Ralph I Zeitoun; Lea Abou Haidar; Ingolf Cascorbi; Nathalie Khoueiry Zgheib
Journal:  Br J Clin Pharmacol       Date:  2019-07-07       Impact factor: 4.335

Review 4.  Standardization can accelerate the adoption of pharmacogenomics: current status and the path forward.

Authors:  Kelly E Caudle; Nicholas J Keeling; Teri E Klein; Michelle Whirl-Carrillo; Victoria M Pratt; James M Hoffman
Journal:  Pharmacogenomics       Date:  2018-06-19       Impact factor: 2.533

Review 5.  Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity.

Authors:  Volker M Lauschke; Yitian Zhou; Magnus Ingelman-Sundberg
Journal:  Pharmacol Ther       Date:  2019-01-22       Impact factor: 12.310

6.  An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes.

Authors:  Sam Mostafa; Carl M J Kirkpatrick; Keith Byron; Leslie Sheffield
Journal:  J Neural Transm (Vienna)       Date:  2018-09-06       Impact factor: 3.575

Review 7.  Pharmacogenomics of chronic obstructive pulmonary disease.

Authors:  Craig P Hersh
Journal:  Expert Rev Respir Med       Date:  2019-04-08       Impact factor: 3.772

8.  Pharmacogenetics and Practice: Tailoring Prescribing for Safety and Effectiveness.

Authors:  Cathy R Fulton; Marelize Swart; Thomas De Luca; Stephanie N Liu; Kimberly S Collins; Zeruesenay Desta; Brandon T Gufford; Michael T Eadon
Journal:  J Nurse Pract       Date:  2018-11-02       Impact factor: 0.767

Review 9.  CYP2D6 polymorphism and its impact on the clinical response to metoprolol: A systematic review and meta-analysis.

Authors:  Maxime Meloche; Michael Khazaka; Imad Kassem; Amina Barhdadi; Marie-Pierre Dubé; Simon de Denus
Journal:  Br J Clin Pharmacol       Date:  2020-04-05       Impact factor: 4.335

Review 10.  Pharmacogenomics.

Authors:  Dan M Roden; Howard L McLeod; Mary V Relling; Marc S Williams; George A Mensah; Josh F Peterson; Sara L Van Driest
Journal:  Lancet       Date:  2019-08-05       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.